Watchlist Price Alert

TG Therapeutics Inc. (TGTX)

NASDAQ: TGTX · Real-Time Price · USD

35.72

0.58 (1.65%)

At close: May 29, 2025, 3:59 PM

35.26

-1.29%

After-hours: May 29, 2025, 07:45 PM EDT

1.65% (1D)

Bid	35.21
Market Cap	5.67B
Revenue (ttm)	386.39M
Net Income (ttm)	39.15M
EPS (ttm)	0.25
PE Ratio (ttm)	142.88
Forward PE	19.72
Analyst	Buy

Ask	36.32
Volume	1,191,610
Avg. Volume (20D)	3,127,531
Open	35.47
Previous Close	35.14
Day's Range	34.83 - 36.06
52-Week Range	15.16 - 46.48
Beta	2.21

About TGTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TGTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TGTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

-13.26%

TG Therapeutics shares are trading lower after the... Unlock content with Pro Subscription

2 months ago

+14.39%

TG Therapeutics shares are trading higher after the company reported better-than-expected Q4 sales results.

News

1 day ago · seekingalpha.com

TG Therapeutics: Estimates Could Soon Be Raised Again

TG Therapeutics remains on track, with Q1 revenue matching my model and potential for 110% growth in 2025 if price increases hold. Analyst estimates for 2025 revenue have risen sharply, and Q2 expecta...

3 weeks ago · benzinga.com

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show

TG Therapeutics Inc TGTX on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents.

3 weeks ago · fool.com

Why TG Therapeutics Stock Was Tumbling Today

A near-doubling of revenue and a flip into profitability on the bottom line apparently weren't good enough for TG Therapeutics (TGTX -12.32%) shareholders on Monday.

3 weeks ago · seekingalpha.com

TG Therapeutics: Share Price Slip On Q1 Earnings Unsurprising Given Challenges

TG Therapeutics' Q1 2025 earnings report showed strong revenue growth, with Briumvi net revenues rising to $119.7m, prompting an increase in full-year revenue guidance. Despite a >15% drop in stock va...

3 weeks ago · seekingalpha.com

TG Therapeutics, Inc. (TGTX) Q1 2025 Earnings Call Transcript

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Jenna Bosco - Chief Communications Officer Michael Weiss - Chairman and Chief Executiv...

3 weeks ago · zacks.com

TG Therapeutics (TGTX) Lags Q1 Earnings Estimates

TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago.

1 month ago · zacks.com

TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.